Facial neuralgia

Summary

Facial neuralgia (MONDO:0001818) is a disease and 2 clinical trials. Top therapeutic interventions include dextromethorphan. A subtype of facial nerve disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	facial neuralgia
Mondo ID	MONDO:0001818
EFO	EFO:0009380
MeSH	D005156
DOID	DOID:13865
SNOMED CT	4151000119102
UMLS	C0015467
MedGen	5099
GARD	0023014
Anatomy (UBERON)	UBERON:0001647
Is cancer (heuristic)	no

Also known as: facial nerve neuralgia · neuralgia of facial nerve

Disease family

This is a subtype of facial nerve disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › cranial nerve neuropathy › facial nerve disorder › facial neuralgia

Related subtypes (8): geniculate ganglionitis, facial nerve neoplasm, Bell’s palsy, facial hemiatrophy, clonic hemifacial spasm, Melkersson-Rosenthal syndrome, Mobius syndrome, isolated facial myokymia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00001725	PHASE2	COMPLETED	Studies of Dextromethorphan and Topiramate to Treat Oral and Facial Pain
NCT01932255	Not specified	WITHDRAWN	CSF Leak Following Microvascular Decompression: the Benefit of Routine Postoperative Lumbar Tap

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DEXTROMETHORPHAN	4	3